Abstracts tagged "remission"

Abstract Number: 2477 • 2014 ACR/ARHP Annual Meeting
Integrating Treatment Goals of Physicians, Patients, and Payers during Treatment with Golimumab in Patients with Rheumatoid Arthritis
B Combe¹, DJ Veale², R Burgos-Vargas³, G Szűcs⁴, M Leirisalo-Repo⁵, R Yao⁶, S Huyck⁶, R Lyu⁶, M Govoni⁷, N Vastesaeger⁸ and HH Weng⁶, ¹Monpellier University Hospital, Montpellier, France, ²Consultant Rheumatologist, St. Vincent’s University Hospital, Dublin, Ireland, ³Cliditer S.A. de C.V. and Hospital General de Mexico, Mexico City, Mexico, ⁴University of Debrecen Faculty of Medicine, Debrecen, Hungary, ⁵Department of Medicine, Division of Rheumatology, Helsinki University Central Hospital, Helsinki, Finland, ⁶Merck & Co., Inc., Whitehouse Station, NJ, ⁷MSD Italy, Rome, Italy, ⁸MSD Belgium, Brussels, Belgium
Background/Purpose Physicians, patients, and payers may have different ideas about what constitutes successful treatment and how treatment goals should be defined for rheumatoid arthritis (RA).…
Abstract Number: 2423 • 2014 ACR/ARHP Annual Meeting
Prevalence of Subclinical Synovitis Detected By Ultrasound in Rheumatoid Arthritis and Psoriatic Arthritis Patients Receiving Anti-TNF-α Therapy with Extended Interval of Administration
José M. Senabre-Gallego¹, José Rosas-Gómez de Salazar¹, Esteban Salas-Heredia¹, Gregorio Santos-Soler¹, Francisca Llinares-Tello², Carlos Santos-Ramirez³, Mabel Sánchez-Barrioluengo⁴, Xavier Barber-Vallés⁵, Rafaela Ortega³, Ana Pons¹, Catalina Cano¹ and Maria Luisa Lorente-Betoret¹, ¹Rheumatology, Hospital Marina Baixa, Villajoyosa, Spain, ²Laboratory, Hospital Marina Baixa, Villajoyosa, Spain, ³Rheumatology, Hospital Marina Salud, Denia, Spain, ⁴Ingenio (CSIC-UPV), Universitat Politècnica de València, Valencia, Spain, ⁵Center of Operations Research, University Miguel Hernández, Elche, Spain
Background/Purpose To estimate the prevalence of subclinical synovitis detected by ultrasound in rheumatoid arthritis (RA) and psoriatic arthritis (PsA) patients in clinical remission receiving anti-TNFα…
Abstract Number: 2396 • 2014 ACR/ARHP Annual Meeting
Treat to Target in Routine Clinical Practice
Mohammad Solaiman¹, Olga Semenova¹, Helen Thompson¹, Joanne Cunnington¹, Elaine Baguley², Sathish Kallankara³, Olanbambo Ogunbambi¹ and Yusuf Patel⁴, ¹Rheumatology, Hull Royal Infirmary, Hull, United Kingdom, ²Anlaby Road, Hull Royal Infirmary, Hull, United Kingdom, ³Rheumatology, Hull Yoyal Infirmary, Hull, United Kingdom, ⁴Department of Rheumatology, Hull and East Yorkshire NHS Trust, Hull East Yorkshire, United Kingdom
Background/Purpose: In order to overcome obstacles with overbooked outpatient clinics and lack of capacity to see rheumatoid patients frequently for treatment escalation, we established a…
Abstract Number: 2870 • 2013 ACR/ARHP Annual Meeting
Higher Disease Activity and Serum Levels Of Angiogenic Factors In Patients With Rheumatoid Arthritis In Clinical Remission With Synovitis On Ultrasound
Julio Ramirez¹, Virginia Ruiz-Esquide², Isaac Pomés³, Raquel Celis⁴, Jaume Pomés³, Sonia Cabrera¹, M. Victoria Hernández⁵, Oscar M Epis⁶, Jose L. Pablos⁷, Raimon Sanmarti¹ and Juan D. Cañete², ¹Arthritis Unit. Rheumatology Department, Hospital Clínic of Barcelona, Barcelona, Spain, ²Rheumatology, Hospital Clinic, Barcelona, Spain, ³Radiology, Hospital Clínic, Barcelona, Spain, ⁴Arthritis Unit, Rheumatology Department, Arthritis Unit, Rheumatology Dpt, Hospital Clinic of Barcelona and IDIBAPS, Barcelona, Spain, ⁵Arthritis Unit, Department of Rheumatology, Hospital Clinic, Barcelona, Barcelona, Spain, ⁶A.O. Ospedale Niguarda Cà Granda, Milan, Italy, ⁷Servicio de Reumatología, Instituto de Investigación Hospital 12 de Octubre (I+12), Madrid, Spain
Background/Purpose: To identify and characterize subclinical synovitis in patients with rheumatoid arthritis in clinical remission using power Doppler ultrasound and serum levels of angiogenic factors.…
Abstract Number: 2803 • 2013 ACR/ARHP Annual Meeting
Can Ultrasonographic Findings Predict Response To Tumor Necrosis Factor-α Inhibitor Treatment In Rheumatoid Arthritis?
Nevsun Inanc^1,2, Gülsen Ozen² and Haner Direskeneli³, ¹Department of Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, ²Rheumatology, Marmara University School of Medicine, Istanbul, Turkey, ³Rheumatology, Marmara University, School of Medicine, Istanbul, Turkey
Background/Purpose: Tumor necrosis factor-α inhibitors (TNFi) are highly effective in patients with rheumatoid arthritis (RA), while not effective in all, with predictors of response being…
Abstract Number: 2276 • 2013 ACR/ARHP Annual Meeting
Does Socioeconomic Status Affect Outcomes In Early Rheumatoid Arthritis? Data From An Inception Cohort
Grace Yang¹, Vivian P. Bykerk², J. Carter Thorne³, Gilles Boire⁴, Diane Tin⁵, Carol A. Hitchon⁶, Edward Keystone⁷, Boulos Haraoui⁸ and Janet E. Pope⁹, ¹Medicine, Western University of Canada, London, ON, Canada, ²Medicine, Mount Sinai Hospital/University of Toronto, Toronto, ON, Canada, ³Southlake Regional Health Centre, Newmarket, ON, Canada, ⁴Rheumatology Division, Centre Hospitalier Universitaire de Sherbrooke, Université de Sherbrooke, Sherbrooke, QC, Canada, ⁵The Arthritis Program, Southlake Regional Health Centre, Newmarket, ON, Canada, ⁶Rheumatology, University of Manitoba, Winnipeg, MB, Canada, ⁷Rebecca MacDonald Centre for Arthritis and Autoimmune Disease, University of Toronto, Toronto, ON, Canada, ⁸Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, ⁹St Joseph Health Care, London, ON, Canada
Background/Purpose: Assess the impact of socioeconomic status (SES) on outcomes in patients with early inflammatory arthritis using data from the Canadian Early Arthritis Cohort (CATCH)…
Abstract Number: 1522 • 2013 ACR/ARHP Annual Meeting
Remission In Spondyloarthritis : ASDAS and Basdai Thresholds From a Prospective Real Life Study
Marie Godfrin-Valnet¹, Marc Puyraveau² and Daniel Wendling¹, ¹Service de Rhumatologie, Minjoz University Hospital, Besancon, France, ²Clinical Methodology Center, CHU, Besançon, France
Background/Purpose: Remission is the current target of management of chronic rheumatic diseases. Whereas in rheumatoid arthritis remission criteria have been recently proposed, in spondyloarthritis, no…
Abstract Number: 1461 • 2013 ACR/ARHP Annual Meeting
Corticosteroid Use In Rheumatoid Arthritis Patients On Infliximab: Treatment Implications Based On A REAL-WORLD Canadian Population
Boulos Haraoui¹, Algis V Jovaisas², William G. Bensen³, Rafat Y. Faraawi⁴, John T. Kelsall⁵, Sanjay Dixit⁶, Emmanouil Rampakakis⁷, John S. Sampalis⁷, Francois Nantel⁸, Susan M. Otawa⁹, Allen J. Lehman⁹ and May Shawi¹⁰, ¹Centre Hospitalier de l’Université de Montréal, Montreal, QC, Canada, ²Division of Rheumatology, University of Ottawa, Ottawa, ON, Canada, ³Department of Medicine, Division of Rheumatology, Clinical Professor, McMaster University, Hamilton, ON, Canada, ⁴Rheumatologist, KW Musculoskeletal Research Inc., Kitchener, ON, Canada, ⁵Mary Pack Arthritis Centre, Vancouver, Vancouver, BC, Canada, ⁶McMaster University, Hamilton, ON, Canada, ⁷JSS Medical Research, Montreal, QC, Canada, ⁸Janssen Inc., Toronto, ON, Canada, ⁹Medical Affairs, Janssen Inc., Toronto, ON, Canada, ¹⁰Medical Affairs, Janssen Canada Inc, Toronto, ON, Canada
Background/Purpose: The Canadian Rheumatology Association1 recommends that addition of corticosteroids (CS) should be considered only for the shortest period possible in rheumatoid arthritis (RA) patients…
Abstract Number: 1332 • 2013 ACR/ARHP Annual Meeting
Metaflammation, PEDF and Chemerin: Potential Systemic Factors Which Link Obesity To Response To Therapy In Early Rheumatoid Arthritis
Elisa Gremese, Barbara Tolusso, Anna Laura Fedele, Maria Rita Gigante, Angela Carbonella, Silvia Canestri, Clara Di Mario and Gianfranco Ferraccioli, Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome, Italy
Background/Purpose: Obesity per se is a systemic, low-grade inflammatory state and the adipose tissue is an endocrine organ that releases bioactive substances, including pro-inflammatory cytokines,…
Abstract Number: 1336 • 2013 ACR/ARHP Annual Meeting
The Safety and Feasibility Of a Treat-To-Target Strategy Aimed At Achieving a Simplified Disease Activity Index Of ¡Ü3.3 While Administering Entecavir In Rheumatoid Arthritis Complicated By Hepatitis B Virus
Yukitomo Urata¹, Yoshihide Nakamura^2,3 and Ken-ichi Furukawa⁴, ¹Seihoku Central Hospital, United Municipalities of Tsugaru, Gosyogawara, Japan, ²Hirosaki University Graduate School of Medicine, Hirosaki, Japan, ³Orthopaedic Surgery, Seihoku Central Hospital, United Municipalities of Tsugaru, Gosyogawara, Japan, ⁴Pharmacology, Hirosaki University Graduate School of Medicine, Hirosaki, Japan
Background/Purpose: To elucidate the safety and feasibility of a treat-to-target (T2T) strategy aimed at achieving a simplified disease activity index (SDAI) of ≤3.3 while administering…
Abstract Number: 436 • 2013 ACR/ARHP Annual Meeting
Efficacy and Safety Study Of a Sequential Therapy Of Tocilizumab and, If Initially Inadequately Responded To Tocilizumab, Followed By Rituximab In Patients With Rheumatoid Arthritis and Inadequate Response To Traditional Disease Modifying Anti-Rheumatic Drugs (MIRAI)-Interim Analysis 2
Thomas Doerner¹, Hans Peter Tony², Hendrik Schulze-Koops³, Jörg Kaufmann⁴, Peter Kaestner⁵, Herbert Kellner⁶, Reiner Kurthen⁷, S. Wagner⁸, Marvin A. Peters⁹ and Christof Iking-Konert¹⁰, ¹Dept Int Med (Charite), Humdoldt Univ, Berlin, Germany, ²Rheumatology/Immunology, University of Würzburg, Würzburg, Germany, ³Division of Rheumatology, University of Munich, Munich, Germany, ⁴Ambulant Centres for Rheumatology, Rheumatologist, Ludwigsfelde, Germany, ⁵Outpatient Department of Rheumatology, Ambulantes Rheumazentrum Erfurt, Germany,, Erfurt, Germany, ⁶Centre for Inflammatory Joint Diseases, Munich, Germany, ⁷Rheumapraxis, Aachen, Germany, ⁸Internistische Schwerpunktpraxis für Rheumatologie, Halle, Germany, ⁹Roche Pharma AG, Grenzach-Wyhlen, Germany, ¹⁰Department of Rheumatology, University Hospital Hamburg Eppendorf, Hamburg, Germany
Background/Purpose: The MIRAI study evaluates a sequential exposure to two defined biologics under rigorous study conditions within a homogeneous population of patients (pts) who inadequately…
Abstract Number: 419 • 2013 ACR/ARHP Annual Meeting
A Long Term Observation Of Rheumatoid Arthritis Who Developed Methotrexate Related Lymphoproliferative Disorders
Yukiko Kamogawa¹, Kyohei Nakamura², Ryu Watanabe², Tsuyoshi Shirai¹, Yoko Fujita³, Yuko Shirota⁴, Noriko Fukuhara¹, Hiroshi Fujii², Shinichiro Saito⁵, Tomonori Ishii² and Hideo Harigae², ¹Tohoku University, Sendai, Japan, ²Department of Hematology and Rheumatology, Tohoku University, Sendai, Japan, ³Department of Hematolgy and rheumatolgy, Tohoku University, Sendai, Japan, ⁴Department of Hematology and Rheumatolgy, Tohoku University, Sendai, Japan, ⁵Department of hematology and rheumatology, Tohoku University, Sendai, Japan
Background/Purpose: Methotrexate (MTX) has been increasingly administered by patients with rheumatoid arthritis (RA). In rare cases, we experience development of malignant lymphoma in patients treated…
Abstract Number: 371 • 2012 ACR/ARHP Annual Meeting
Treat-to-Target Strategy Aiming At Achievement of Structural and Functional Remission in Patients with Active Elderly-Onset Rheumatoid Arthritis
Takahiko Sugihara¹, Tatsuro Ishizaki², Tadashi Hosoya¹, Shoko Iga¹, Waka Yokoyama¹, Fumio Hirano¹, Nobuyuki Miyasaka³ and Masayoshi Harigai⁴, ¹Department of Medicine and Rheumatology, Tokyo Metropolitan Geriatric Hospital, Tokyo, Japan, ²Human Care Research Team, Tokyo Metropolitan Institute of Gerontology, Tokyo, Japan, ³Department of Medicine and Rheumatology and Global Center of Excellence Program, Tokyo Medical and Dental University, Tokyo, Japan, ⁴Dept of Pharmacovigilance, Tokyo Medical and Dental University, Tokyo, Japan
Background/Purpose: Treat-to-target is the consensus treatment strategy for patients with rheumatoid arthritis (RA), but supporting evidence for treat-to-target strategy in elderly RA patients in clinical…
Abstract Number: 109 • 2012 ACR/ARHP Annual Meeting
Does Joint Sonography Really Add Clinically Important Information Beyond Clinical Joint Examination?
Miriam Gärtner¹, Helga Radner², Gabriela Supp², Peter Mandl³, Daniel Aletaha¹, Klaus P. Machold⁴ and Josef S. Smolen⁵, ¹Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Department of Internal Medicine III; Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ³Rheumatology, Medical University of Vienna, Vienna, Austria, ⁴Internal Medicine III, Medical University of Vienna, Vienna, Austria, ⁵Division of Rheumatology, Department of Internal Medicine III,, Medical University of Vienna and Hietzing Hospital, Vienna, Austria
Background/Purpose: Sonographic assessment of joint activity in patients with rheumatoid arthritis (RA) is considered to be more sensitive than the respective clinical assessment. However, this…
Abstract Number: L7 • 2012 ACR/ARHP Annual Meeting
Tapering TNF-Blockers in Established Rheumatoid Arthritis Patients in DAS28 Remission: Results of a DAS28-Driven Step-Down Strategy Randomized Controlled Trial
Bruno Fautrel¹, Thao Pham², Florence Tubach³, Toni Alfaiate⁴, Jacques Morel⁵, Emmanuelle Dernis⁶, Xavier J. Puechal⁷, Philippe Gaudin⁸ and Xavier Mariette⁹, ¹Rheumatology, UPMC - Paris 6 University, Paris, France, ²Rheumatology Department, Sainte Marguerite Hospital, Marseille, France, ³Département d'Epidémiologie Biostatistique et Recherche Clinique, APHP, Hôpital Bichat, Paris, France, ⁴Biostatistics, Bichat Hospital, AP-HP, Paris, France, ⁵Dpartment of Rheumatology, Lapeyronie Hospital, Montpellier, France, ⁶Centre Hospitalier, Le Mans, France, ⁷Le Mans Hospital, Le Mans, France, ⁸Rheumatology Department, CHU Hôpital Sud, Grenoble Teaching Hospital, Echirolles, France, ⁹Rheumatology Service, Bicêtre University Hospital, Le Kremlin Bicetre, France
Background/Purpose: Step-down therapeutic strategies are often considered in established rheumatoid arthritis (RA) once remission is achieved but are associated with a potential risk of relapse…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].